US, China key to GSK's consumer venture with Pfizer

LONDON: The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.

"The U.S. and China are really two of the key value drivers of the deal because it's where Pfizer has critical mass and a significant amount of their key brands," he said in an interview, noting the new entity will be the No.1 player in the United States and No.2 in China."U.S. and China are must-win markets."

The new, yet-to-be-named company will have annual sales of 9.8 billion pounds and more than 7 percent of the global consumer health market, with brands also including Centrum vitamins and Sensodyne toothpaste.Pfizer's Centrum is already the leading multivitamin in China, while Caltrate is the No.2 calcium supplement in what is one of the world's most calcium-deficient populations, McNamara said.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

White House sees 'headway' on US-China trade ahead of new talks this weekWASHINGTON (REUTERS) - The United States and China'expect to make more headway' in trade talks this week, White House economic adviser Larry Kudlow said on Tuesday (April 2) as the top US business lobbying group said differences over an enforcement mechanism and the removal of US tariffs were still obstacles to a deal.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

World stocks rally to six-month highs on US-China trade optimismWorld stocks rallied to six-month highs on Wednesday as investors cheered signs of progress in U.S.-China trade talks and reassuring economic ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »